AliveDx Suisse S.A. and Medlinks Consulting Joint Stock Company have signed a distribution agreement, which will enable Medlinks to distribute the MosaiQ® solution in South Vietnam. The distribution agreement takes effect immediately.
AliveDx is dedicated to expanding its reach and presence across various regions and to creating clinical and economical value for clinicians, helping them to shorten the time to diagnosis. This strategic collaboration with an important partner in South Vietnam is a testimony to the company’s commitment to supporting the healthcare sector and enhancing patient care.
The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.
“We are proud to announce this partnership with another key player in the Asian market. We look forward to working with Medlinks and playing a strategic role in improving patients’ lives in the region,” said Manuel O. Méndez, AliveDx’s CEO.
“It is a great pleasure to work with Dr. Thuy and the Medlinks team in Vietnam and to introduce the innovative MosaiQ technology. The MosaiQ solution will bring state-of-the-art microarray, multiplexing technology to the region, marking a revolutionary change in the diagnosis of autoimmune diseases and soon allergy,” said Khaled Hamed, Head of Global Emerging Markets at AliveDx.
Established in 2019, Medlinks is headquartered in Ho Chi Minh City, South Vietnam. It operates nationally, with branch offices in Hanoi and Danang. Medlinks is committed to investing in customer training, education and clinical evaluation support; ensuring the delivery of quality products and services; and growing with its customers and business partners.
“We are honored to collaborate with AliveDx. As part of our company’s objectives, we are delving into the in-vitro diagnostic industry. Adding the AliveDx solution to our portfolio marks our advancement into the immunology diagnostic segment. We are confident that the MosaiQ solution will empower us to deliver best-in-class technology to the healthcare sector in Vietnam, ultimately benefiting patients,” said Dr. Tran Xuan Thuy, founder and CEO of Medlinks.
To learn more, please visit the website the Medlinks website.
